Related Experiment Videos
[Deptropine still prescribed for 0-4 year olds]
1Rijksuniversiteit Groningen, afd. Sociale Farmacie en Farmaco-epidemilogie, Antonius Deusinglaan 2, 9713 AW Groningen.
Nederlands Tijdschrift Voor Geneeskunde
|January 6, 2001
Summary
Despite negative reporting, deptropine prescriptions for young children decreased significantly, while inhaled beta-2 adrenergic agonists and glucocorticosteroids saw increased use in pediatric asthma management.
Area of Science:
- Pediatric Pulmonology
- Pharmacovigilance
- Drug Utilization Studies
Context:
- Negative reporting and removal of deptropine from pediatric asthma guidelines prompted an investigation into prescription trends.
- The study period spanned 1994-1999, encompassing the changes in clinical recommendations.
Purpose:
- To assess the impact of negative reporting and guideline changes on deptropine prescription rates in young children (0-4 years).
- To evaluate the concurrent changes in the utilization of alternative asthma medications during the same period.
Summary:
- Prescription data from 1994-1999 revealed a decline in deptropine use among 0-4 year olds, from 14.9% to 4.8%.
- Concurrently, the use of inhaled beta-2 adrenergic agonists increased from 2.4% to 6.8%, and inhaled glucocorticosteroids rose from 1.8% to 7.0% in the same age group.
Impact:
- Deptropine continued to be prescribed, though at a reduced frequency, indicating a lag in guideline adoption.
- The increasing use of inhaled corticosteroids and beta-2 agonists suggests a shift towards evidence-based asthma pharmacotherapy in young children.